Form D · Pharmaceuticals
SINOCOM PHARMACEUTICAL, INC.
Central, K3 · CIK 0001434017
Offering snapshot reported Dec 14, 2009 · SEC filing
- Reported sold
- $15M Offering amount: $15M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 3, 2009 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 14, 2009 | Initial | $15,000,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $1.64M (estimated)
- Form D file number
- 021-136867
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| DBS Nominees (Private) Limited | None | |
| Pricewaterhouse Coopers (Shenzen) Limited (acting as advisor to issuer's Hong Kong subsidiary) | None | |
| Rich Prospect Investments Limited | None | |
| SEAVI Advent Equity V (A) Ltd | None |
Source: Form D, filed Dec 14, 2009. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Xuexiang Ai | Director, Executive |
| Tuck Wing Pang | Director, Executive |
| Chi Kwong Wan | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
Room 3, 21/F, Far East Consortium Bldg 121 Des Voeux Road
Central, K3, 99999
Central, K3, 99999